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Abstract
Background: The persistent evolution of highly pathogenic avian influenza (HPAI) highlights the need for novel vaccination
techniques that can quickly and effectively respond to emerging viral threats. We evaluated the use of optimized consensus
influenza antigens to provide broad protection against divergent strains of H5N1 influenza in three animal models of mice,
ferrets, and non-human primates. We also evaluated the use of in vivo electroporation to deliver these vaccines to overcome
the immunogenicity barrier encountered in larger animal models of vaccination.
Methods and Findings: Mice, ferrets and non-human primates were immunized with consensus plasmids expressing H5
hemagglutinin (pH5HA), N1 neuraminidase (pN1NA), and nucleoprotein antigen (pNP). Dramatic IFN-c-based cellular
immune responses to both H5 and NP, largely dependent upon CD8+ T cells were seen in mice. Hemaggutination inhibition
titers classically associated with protection (.1:40) were seen in all species. Responses in both ferrets and macaques
demonstrate the ability of synthetic consensus antigens to induce antibodies capable of inhibiting divergent strains of the
H5N1 subtype, and studies in the mouse and ferret demonstrate the ability of synthetic consensus vaccines to induce
protection even in the absence of such neutralizing antibodies. After challenge, protection from morbidity and mortality
was seen in mice and ferrets, with significant reductions in viral shedding and disease progression seen in vaccinated
animals.
Conclusions: By combining several consensus influenza antigens with in vivo electroporation, we demonstrate that these
antigens induce both protective cellular and humoral immune responses in mice, ferrets and non-human primates. We also
demonstrate the ability of these antigens to protect from both morbidity and mortality in a ferret model of HPAI, in both
the presence and absence of neutralizing antibody, which will be critical in responding to the antigenic drift that will likely
occur before these viruses cross the species barrier to humans.
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Introduction
Efforts to develop vaccines against highly pathogenic avian
influenza (HPAI) highlight several challenges facing the vaccine
development community. Predicting which strains of seasonal
influenza to include in the annual vaccine is a difficult task, and
has on multiple occasions led to the development of an ineffective
or partially protective vaccine. This past year is a good example,
with influenza vaccine coverage approximating a mere 30%. This
prediction is made more difficult with H5N1 HPAI, whose
evolution and migration have been shown to be more complex
than was initially appreciated [1,2]. The timeline for designing and
producing conventional vaccines against an unpredicted emerging
virus would preclude their development during an emerging
epidemic [3]. In addition, humans have no pre-existing immunity
to H5 viruses upon which to build, which may have contributed to
the initial difficulty seen in inducing seroconversion to H5-based
subunit and killed virus vaccines [4,5,6].
An ideal vaccine platform would include technologies that can
be quickly and easily scaled up for mass production, in addition to
a delivery mechanism that can quickly induce seroconversion
against novel antigens. The induction of potent cross-reactive
cellular responses, a challenge facing many vaccine platforms,
could also prove very useful in augmenting absent or incomplete
antibody neutralization.
Conceptually, DNA vaccines have many of these attributes.
Their progress to the clinic, however, has been slowed by
difficulties in reproducing the potent immune responses seen in
small animals to other models of vaccination. In order to address
the technical hurdles associated with limited vaccine immunoge-
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constructs with constant-current in vivo electroporation (IVE) and
analyzed immunogenicity in mouse, ferret, and primate models of
vaccination. Electroporation has classically been used in vitro to
enhance the delivery of plasmid to cells in culture. Recent studies,
however, have shown its promise in enhancing the delivery and
expression of plasmid DNA in vivo, leading to the generation of
more potent immune responses [7,8,9].
In addition, we asked several important questions regarding
vaccine-induced correlates of immunity to pathogenic influenza.
These include the ability of cell-mediated immunity to protect
against HPAI in the presence of the severe cytokine dysregulation
associated with H5N1 influenza–a question thus far asked only in
murine challenge models [10,11,12] and extended here to ferrets.
In order to address these questions, we have developed several
consensus influenza antigens, several of which have been previously
described [13]. These include an H5 hemagglutinin construct
(pH5H1), whose component sequences include 16 predominantly
clade 1 H5N1 sequences that have infected and proven fatal in
humans and a consensus N1 neuraminidase construct (pN1NA),
generated from over 40 influenza A sequences. We also present a
construct based on consensus influenza A nucleoprotein (pNP),
which has not been previously described.
Materials and Methods
DNA Vaccines
pH5HA and pN1NA have been previously described [13]. pNP
was designed and constructed in a similar manner. Briefly,
influenza A matrix 2 and nucleoprotein sequences were down-
loaded from the Los Alamos National Laboratory Influenza
Sequence Database. Sequences were chosen from geographically
diverse locations. MegAlign (DNASTAR, Madison, WI) was used
to align the sequences and generate a consensus sequence. The
consensus ectodomain of the matrix 2 antigen was fused to the full-
length consensus nucleoprotein, and the construct optimized for
expression, including codon and RNA optimization (GeneArt,
Regensburg, Germany). The homology between these constructs
and the original sequences is shown in Table 1. The construct
elicits no antibody responses as determined by ELISA and HI.
Each of the constructs was subcloned into the pVax expression
vector. For the mouse studies, endotoxin-free DNA preparations
were made using Qiagen Giga prep columns (Valencia, CA) [14].
For the ferret and non-human primate studies, DNA preparations
were made at VGX Pharmaceuticals, Inc. (The Woodlands, TX)
as previously described [7], and formulated at 10 mg/mL in water
plus 1% w/w poly-L-glutamate sodium salt.
Mouse Studies. The quadriceps muscles of 6–8 week old
female BALB/C or C57BL/6 mice (Jackson Laboratory) were
injected 3 times, two weeks apart, with 25 mg of plasmid-encoded
antigen and electroporated as previously described [15]. Briefly,
square-wave pulses were delivered through a triangular 3-
electrode array consisting of 26-gauge solid stainless steel
electrodes. Two constant-current pulses of 0.1 Amps were
delivered for 52 msec/pulse separated by a 1 sec delay using the
CELLECTRAH adaptive constant current device (VGX
Pharmaceuticals, The Woodlands, TX). One month later, mice
were sacrificed for immunogenicity studies or challenged with
influenza (see below). Mice were housed and treated in a
temperature-controlled, light-cycled facility at the University of
Pennsylvania, and cared for under the guidelines of the NIH and
the University of Pennsylvania.
Ferret Studies. Male ferrets (Triple F Farms, Sayre, PA), 4–6
month old, weight average 1.260.2 kg at the start of the study
were immunized three times in alternate biceps femoris muscles,
each one month apart, with 200 mg of DNA per antigen (and/or
vector control) and electroporated as previously described [16].
Briefly, electroporation was delivered through a pentagonal 5-
electrode array consisting of 21-gauge solid stainless steel electrodes.
Three constant-current pulses of 0.5 Amps were delivered for
52 msec/pulse separated by a 1 sec delay using the CELLECTRAH
adaptive constant current device (VGX Pharmaceuticals, The
Woodlands, TX). Ferrets were housed and cared for at
BIOQUAL, Inc. (Rockville, MD). These facilities are accredited
by the American Association for the Accreditation of Laboratory
Animal Care International and meet NIH standards as set forth in
the Guidelines for Care and Use of Laboratory Animals.
Macaque Studies. Rhesus macaques were housed at
BIOQUAL, Inc. (Rockville, MD), in accordance with the
standards of the American Association for Accreditation of
Laboratory Animal Care. Animals were allowed to acclimate for
at least 30 days in quarantine prior to any immunization. A group
of five rhesus macaques were immunized at weeks 0 and 4 with
1 mg/construct of pH5HA, pNP, and pN1NA. DNA was
delivered into the semimebranosous muscle followed by in vivo
electroporation using the constant current CELLECTRAH device
(VGX Pharmaceuticals, The Woodlands, TX). Electroporation
conditions were 0.5 Amps, 3 pulses, 52 msec pulse length, with
1 sec between pulses.
Blood collection. Non-human primates. Animals were bled
every two weeks. 10 mL of blood was collected in EDTA tubes,
and peripheral blood mononuclear cells (PBMC) isolated by
standard Ficoll-hypaque centrifugation and re-suspension in
complete culture medium (RPMI 1640 with 2 mM/L L-
glutamine, 10% heat-inactivated fetal bovine serum, 100 IU/mL
penicillin, 100 mg/mL streptomycin, and 55 mM/L b-
mercaptoethanol). Red blood cells (RBC) were lysed with
ammonium chloride-potassium (ACK) lysis buffer (Cambrex
BioScience, East Rutherford, NJ).
ELISpot assay. ELISpot assays were conducted as previously
described [17]. Briefly, ELISpot 96-well plates (Millipore, Billerica,
MA) were coated with a) anti-mouse (R&D Systems, Minneapolis,
MN) or b) anti-human (clone GZ-4, Mabtech, Cincinnati, OH)
interferon- gamma (IFN-c) capture antibody and incubated
overnight at 4uC. The following day, plates were washed with PBS
and blocked for2 hwith R10.2610
5 splenocytes (mouse) orPBMCs
(macaque) from each group were added to each well and stimulated
overnight at 37uC in the presence of R10 peptide (negative control)
or specific peptide antigens (10 mg/mL) (Invitrogen, Carlsbad, CA).
Peptide pools consist of 15-mer peptides overlapping by 11 amino
acids. After 24 h of stimulation, the cells were washed and incubated
Table 1. Hemagglutination Inhibition of H5N1 Influenza
Viruses.
Clade 1 Clade 2.1
2
nd Immunization 3
rd Immunization 3
rd Immunization
pNP ,20 ,20 ,20
pComb 170 (40–320) 600 (160–1280) 210 (40–320)
pVax ,20 ,20 ,20
Hemagglutination inhibition titers in ferrets after the second and third
immunization against a clade 1 (A/Vietnam/1203/04) and clade 2.1 (A/
Indonesia/05/2005) virus. Values shown include the mean and range of values.
doi:10.1371/journal.pone.0002517.t001
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Minneapolis, MN) or b) anti-human (clone 7-B6-1, Mabtech IFN-c
capture antibody). Plates were washed, and streptavidin-alkaline
phosphatase (R&D Systems, Minneapolis, MN) was added to each
welland incubated for2 hatroomtemperature.Plateswerewashed,
and BCIP/NBT chromogen (R&D Systems, Minneapolis, MN) was
added. The plate was then rinsed with distilled water and dried.
Spots werecounted byanautomated ELISpot reader(CTLLimited,
Shaker Heights, OH).
Antibody ELISA assay. 96-well high-binding polystyrene
plates (Corning, Lowell, MA) plates were coated overnight at 4uC
with recombinant protein (2 mg/mL, XpressBio, Thurmont, MD)
diluted in PBS. The next day, plates were washed with PBS,
0.05% Tween 20 (PBST), blocked for 1 h with 3% BSA/PBST,
and incubated with serial dilutions of serum from immunized and
naı ¨ve mice for 1 h at 37uC. Bound IgG was detected using goat
anti-mouse IgG-HRP (Research Diagnostics, Concord, MA) at a
dilution of 1:10000. Bound enzyme was detected by the addition
of the chromogen substrate solution TMB (R&D Systems), and
read at 450 nm on a Biotek (Winooski, VT) EL312e reader.
Hemagglutination Inhibition (HI) Assay. Sera were
treated with receptor-destroying enzyme (RDE) by diluting one
part serum with three parts enzyme and incubated overnight in
37uC water bath. The enzyme was inactivated by 30 min
incubation at 56uC followed by addition of six parts PBS for a
final dilution of 1/10. HI assays were performed in V-bottom 96-
well microtiter plates, using four hemagglutinating units (HAU) of
virus and 1% horse RBC as previously described [18]. The viruses
used for the HI assay are reassortant strains obtained from the
Center for Disease Control and Prevention (CDC), Influenza
branch (Atlanta, GA): A/Viet/1203/2004(H5N1)/PR8-IBCDC-
RG and A/Indo/05/2005 (H5N1)/PR8-IBCDC-RG2.
Determination of Viral Titers for the ferret challenge
study. For RNA isolation, nasal wash samples were spun down
at 10,0006g for 1 hr, liquid poured off and 1 mL of RNA-STAT
60 (Isotex Diagnostics, Friendswood, TX) added. Samples were
then incubated at RT for 5 min and resuspended in 250 mLo f
chloroform by vortexing. The samples were spun down at
10,000 g for 1 hr, the aqueous top-layer removed, 0.5 mL
isopropanol and 10 ml tRNA (10 mg/mL) added and
precipitated overnight at 220uC. Samples were spun down for
1 hr, washed with cold 75% ethanol and respun for another hour.
RNA was resuspended in 30 ml RNAse-free water. For RT-PCR,
10% RNA was added to TaqMan reagents (Applied Biosystems,
Foster City, CA) along with primers and probe (listed below) and
amplified in a 7700 Sequence Detection System (Applied
Biosystems). Briefly, the sample was reverse-transcribed at 48uC
for 30 min., held at 95uC for 10 min., then run for 40 cycles of
95uC for 15 s and 60uC for 1 min. The signal was compared to a
standard curve of known concentrations of RNA starting at 10
6
down to 1 copy/mL and multiplied by 10 giving a detection range
from 20–10
7 copies/mL. All samples were performed in triplicate.
The primers and probe were designed to bind to a highly
conserved region on the nucleoprotein gene.
Primer sequences:
VIETA-U 59 CGT CTC AAG GCA CCA AAC G 39
VIETA-D 59 GTA GAA CCT CCC AAT GCC AC 39
Probe sequence: VIETA-P FAM-GGA ACG CCA GAA
TGC TAC TGA GAT CAG GGC-TAMRA.
Virus Challenge. For the initial murine H5N1 influenza
challenge, isoflurane-anaesthetized mice were intranasally
inoculated with 100 LD50 of A/Hanoi/30408/2005 (obtained
from CDC) in 50 ml MEM/3% BSA at the Public Health Agency
of Canada. The murine H5N1 challenge analyzing correlates of
immunity was conducted at BIOQUAL, Inc. using 10 LD50 of A/
Vietnam/1203/2004. Murine H1N1 challenges were performed
at the University of Pennsylvania. Avertin-anaesthetized mice
were intranasally inoculated with 10 LD50 of A/Puerto Rico/8/34
in 30 ml PBS. CD4+ and CD8+ T cell depletions were performed
using 150 mg of monoclonal antibodies GK1.5 (BD Pharmingen,
San Jose, CA) or 2.43 (purified). All murine challenge groups were
comprised of 10 mice per group. Ferret H5N1 challenges were
performed at BIOQUAL, Inc., with 10
4.7 EID50 of A/Vietnam/
1203/2004. There were four ferrets in each group, and all ferrets
tested seronegative for recently circulating H1N1 and H3N2
viruses. Both mice and ferrets were weighted daily. After
challenge, weights, body temperature, and clinical signs were
recorded daily from day 21 before challenge to day 9 after
challenge and then on days 11 and 14 after challenge.
Results
Murine Immunogenicity and Challenge Studies
IVE appears to be a promising new technology for the delivery
of DNA vaccines [1,19,20,21,22,23,24]. In order to determine if,
combined with our consensus antigens, IVE could induce a potent
immune response against synthetic DNA antigens, we immunized
and electroporated BALB/C mice with each of the individual
vaccine candidates. Figure 1a shows the ELISpot results from
immunized mice. Both pH5HA and pNP are capable of inducing
dramatic (interferon-c-based) cellular immune responses, largely
dependent upon CD8+ T cells, as shown by the loss of interferon-c
secretion in CD8-depletion controls, ELISpots for H5HA were
14786209 vs. 209639 in CD8-depleted mice (average 6SE
mean), while ELISpots for pNP were 26766145 vs. 1516201, in
CD8-depleted mice. pN1NA was also able to elicit a strong cellular
response, eliciting a mean of 571 spots 6384 vs. 41640 in CD8-
depleted mice. Splenocytes from naı ¨ve mice stimulated with these
antigens, and R10 controls for, were all well below the 40-spot
assay threshold (data not shown). In addition, Figure 1b shows the
ability of pH5HA to induce a strong antibody response with an
endpoint titer above 1:64,000. In contrast, neither pN1NA nor
pNP elicited any detectable antibody responses as determined by
ELISA and HI assays (data not shown).
In order to determine if the immune responses elicited by these
synthetic antigens are capable of providing protection from HPAI,
we challenged BALB/C mice with 100 LD50 of the highly
pathogenic H5N1 virus A/Hanoi/30408/2005 (not included as a
component sequence in the design of any consensus immunogen).
Figure 2a shows the survival curve for each group of mice. pN1NA
showed 60% protection from death, while pNP was able to protect
from death 80% of the vaccinated animals, which also exhibited
improved morbidity (decreased weight loss post-challenge, with
the average maximum weight loss in the pNP group at
24.9%62.1%, and in the pN1NA group at 29.9%62.8%, as
shown in Figure 2b). As shown, vaccination with pH5HA offered
complete protection from both morbidity (with no significant
weight loss detected) and mortality.
We next decided to extend these findings to another murine
haplotype while asking several questions regarding the observed
protection. Previous murine studies of vaccination and challenge
with influenza have shown that cellular immune responses can
provide protection from infection-associated morbidity and
mortality [25,26,27,28]. It has also been shown that this protection
can be mediated by either CD4+ or CD8+ T cells [25,26]. This
issue has not been addressed, however, in the context of HPAI,
where severe cytokine dysregulation could potentially impact the
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immunized and electroporated C57BL/6 mice with the pNP
construct and challenged them after depletion of either CD4+ T
cells, CD8+ T cells, both, or neither. These mice were challenged
with an H1N1 virus (A/PR/8/34). As shown in Figure 3a,
protection was seen individually with either CD4+ or CD8+ T
cells, demonstrating in vivo that the synthetic vaccines can induce
cross-reactive CD4+ and CD8+ cellular immune responses (90%
survival in vaccinated, undepleted mice, 80% survival in CD4-
depleted mice, 70% survival in CD8-depleted mice, and 0% survival
in dual-depleted and naı ¨ve controls). Furthermore, challenging a
separategroupofmicewithanH5N1virus(Figure3b)demonstrated
that, in the context of pathogenic influenza and the associated
cytokine dysregulation, both CD4+ and CD8+ subsets together
provide considerably more protection than either alone (75%
survival in vaccinated, undepleted mice, 36% survival in CD4-
depleted mice, 38% survival in CD8-depleted mice, 11% survival in
dual-depleted mice, and 0% survival in naı ¨ve mice). The slower
onset of mortality in H5N1-infected, T cell-depleted mice may
suggestthatcellularimmunitymayplaybotha roleinprotectionand
pathogenesis of avian influenza.
Induction of Cross-Reactive Antibodies
The ferret model of influenza infection is considered to be more
reflective of human disease and a more rigorous challenge model.
Ferrets exhibit similar symptoms to humans infected with
influenza and similar tissue tropism with regards to human and
avian influenza viruses [29]. In this study, three groups of ferrets
were immunized and electroporated with 1) pVax (control), 2) a
combination of pH5HA, pN1NA, and pNP (denoted as pComb in
Figures 4 and 5), or 3) pNP alone. Serum was collected at different
time points throughout the study to detect hemagglutination
inhibition (HI) activity against H5N1 viruses, with HI titers of
greater than 1:40 considered reflective of a protective humoral
immune response. As shown in Table 1, ferrets that received the
pH5HA construct attained protective levels of antibody (mean of
1:170, range 1:40–320) after two immunizations. Following the
third immunization, these titers increased to a mean of 1:600
(range 1:160–1280). We then tested the ability of these constructs
to induce antibodies capable of inhibiting a more divergent H5N1
clade 2 virus. Again, after the third immunization, protective titers
of HI activity reached 1:210 (mean, range 1:40–320). Importantly,
Figure 1. Induction of antigen-specific immune responses in BALB/C mice. (a) Quantification of IFN-c secreting CD8+ T cells at one month
following the final immunization. Splenocytes were stimulated with pools of overlapping peptides spanning the length of the antigen, separated into
multiple pools. Also included are CD8-depleted controls. (b) Endpoint antibody ELISA from serum collected from mice immunized with pH5HA. All
error bars represent 61 standard deviation from the mean, and are representative of three independent experiments.
doi:10.1371/journal.pone.0002517.g001
Figure 2. Results following an H5N1 challenge of immunized
mice. Mice were challenged with 100LD50 of an H5N1 virus (A/Hanoi/
05/2005). (a) Kaplan-Meier curve showing the percent survival in each
group. (b) Average weight loss among the surviving members of each
group (and the weight loss seen in naı ¨ve mice before death). Error bars
represent 1 standard deviation from the mean, and are shown only in
the positive direction for clarity.
doi:10.1371/journal.pone.0002517.g002
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2 viruses in all the animals receiving the consensus HA
immunogen. These data demonstrate for the first time that
synthetic DNA antigens can efficiently induce cross-reactive
antibodies against H5N1 influenza in the ferret model.
Ferret Challenge
One month following the third and final immunization, ferrets
were challenged intranasally with a lethal dose of the HPAI virus
A/Vietnam/1203/04. As shown in Figure 4a, all naı ¨ve animals
had succumbed to infection by day 7, while all of the vaccinated
animals in each group survived through the end of the study.
Figures 4b shows weight loss in each of the infected groups. The
highest degree of protection from weight loss was seen in those
animals with both protective antibodies and broad cellular
immune responses, losing 10.6% body weight 63.4% (compared
to 24.7%61.5% in the control group, p,.05). pNP, which induces
only potent cellular immune responses, was able to provide a
statistically significant degree of protection, with an average weight
loss of 17%61.2% (p,.05). Figure 5 shows viral shedding from
each group on days 1, 3, and 5 post-infection. Each vaccinated
group displayed a statistically significant reduction in viral
shedding by day 5 (p,.01). In group pComb, the mean viral
load was reduced by over 99%. In the group pNP, with protection
based solely on cellular immunity, there was a 90% reduction in
mean viral load. These data support that the vaccine-induced
cellular and humoral immune responses can impact disease and
transmission (viral shedding) associated with pathogenic influenza
infection in the more relevant ferret model.
Primate Immunogenicity
Lastly, while these data provide important insights into the
development of novel vaccine platforms appropriate for HPAI, the
ability to induce these immune responses in larger animals will
dictate their ability to move into clinical evaluation. We next
studied the immunization and electroporation of rhesus macaques
with the consensus influenza antigens. Figure 6 shows the ELISpot
results after two immunizations. Each of the macaques generated
Figure 3. Kaplan-Meier survival curve in mice challenged with (a) H1N1 influenza (A/PR/8/34) and (b) H5N1 influenza (A/Vietnam/
1203/04). All mice were immunized with pNP (except for naı ¨ve) and depleted of CD4+ T cells, CD8+ T cells, both, or neither.
doi:10.1371/journal.pone.0002517.g003
Figure 4. Survival and weight loss following H5N1 ferret challenge. (a) Kaplan-Meier curve of ferrets challenged with an H5N1 virus (A/
Vietnam/1203/04). Ferrets were immunized and electroporated three times with the indicated constructs. One month following the final
immunization, ferrets were challenged intranasally with a lethal dose of an H5N1 influenza virus. (b) Maximum weight loss in each group. Error bars
represent 1 standard deviation from the mean, and are shown only in the positive direction for clarity.
doi:10.1371/journal.pone.0002517.g004
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ELISpot count of over 500 and a maximum above 2100 (mean
spot count 10506662 SEM).
Looking at hemagglutination inhibition activity following only
two immunizations (Figure 7), we see that each of the monkeys
demonstrated HI activity against a similar clade 1 virus, with mean
titers of 1:160 (range 1:8–320). There is also significant inhibition
of a clade 2.1 virus (A/Anhui/01/05, mean inhibition 1:80, range
1:40–160), and detectable inhibition in each macaque against a
more divergent clade 2.1 virus (A/Indonesia/05/05, mean
inhibition 1:36, range 1:20–80). The ability of DNA to induce
potent and cross-reactive immune responses against influenza in
primates is of considerable interest and may provide a useful tool
to influenza prevention efforts.
Discussion
The ability to induce cross-reactive cellular and humoral immune
responses in humans would be a significant advance in the
development of next-generation vaccines [30]. This is especially
true for seasonal and pathogenic influenza–particularly H5N1
influenza viruses, which have become endemic in many countries.
Consensus vaccines offer a novel means of inducing such responses.
These vaccines are designed using a large number of primary viral
sequences, and as such contain the most highly conserved
characteristics of each. This is reflected in Table 2, which quantifies
the advantages of using consensus constructs, and their increasing
homology against primary strains of influenza. These constructs
havebeenshownnotonlytoinducestrongCD8+and CD4+cellular
immune responses, but that these responses are in fact more cross-
reactive than their individual component antigens [31,32,33,34].
However, a majority of these studies have focused on HIV, and can
not realistically address the ability of these synthetic vaccines to
induce protective antibody responses in vivo.
The absence of any prior immunity to H5N1 viruses
significantly inhibited the initial development of subunit and kill-
virus vaccines capable of demonstrating in vitro antibody reactivity
to H5N1 viruses. Unfortunately, the continued evolution of H5N1
viruses increases the possibility that these stockpiled vaccines will
have poor cross-reactivity to a virus eventually capable of crossing
the species barrier. Because currently approved vaccination
strategies require a significant production timeline, and given the
mortality rate and emerging data on surveillance of H5N1
influenza evolution, significant measures need to be taken in
anticipation of potential pandemics. DNA vaccines offer such an
Figure 5. Viral shedding following challenge with HPAI. Nasal washes were collected every other day immediately following challenge. RT-
PCR was performed to determine the RNA copy number from each group.
doi:10.1371/journal.pone.0002517.g005
Figure 6. Induction of antigen-specific immune responses in
rhesus macaques. Purified PBMCs were analyzed two weeks
following the second immunization for antigen-specific interferon-c
responses. Values from media-stimulated controls were subtracted from
the corresponding antigen-stimulated monkey samples.
doi:10.1371/journal.pone.0002517.g006
Figure 7. Hemagglutination inhibition activity in rhesus
macaques following two immunizations. HI activity is shown for
clade 1 (A/Vietnam/1203/04), clade 2.1 (A/Anhui/01/05), and a more
divergent clade 2.1 (A/Indonesia/05/05). Naı ¨ve monkeys showed no
detectable HI activity against any of the indicated strains.
doi:10.1371/journal.pone.0002517.g007
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than other available technologies.
Our results here demonstrate the ability of synthetic consensus
constructs, with in vivo electroporation, to induce protective cellular
and humoral immune responses in small and large animals models
of vaccination. Studies with pH5HA in the mouse demonstrate the
ability of synthetic consensus HA to provide immunity from a
clade-matched pathogenic challenge. These responses, in both
ferrets and macaques, also demonstrate the ability of synthetic
consensus antigens to induce responses capable of inhibiting
divergent viruses of the H5N1 subtype.
While antibody-based vaccines are the only current means by
which to provide sterilizing immunity, a vaccine to reduce the
morbidity and mortality associated with a rapidly spreading
pathogenic virus would be a valuable tool in combating a pandemic.
In addition, reducing the viral load and duration of disease
could also reduce the rate of viral transmission, giving public
health officials additional time in a dangerous situation. And while
simple point mutations can render an antibody-based vaccine
ineffective, cellular immune responses, considerably more promis-
cuous than their antibody counterpart, and can recognize several
variants of the same epitope.
In studying the pNP-induced correlates of immunity to H1N1
influenza in the mouse, we have shown here that these synthetic
consensus vaccines are able to induce both CD4+ and CD8+
cellular immune responses capable of providing protection from
influenza infection. Extending these experiments to an H5N1
murine challenge model suggested that these responses, while
protective, are both required in responding to more highly
pathogenic influenza viruses. Importantly, this cellular protection
was reproducible in the more prognostic ferret model of
pathogenic influenza infection, demonstrating for the first time
significant protection from weight loss and viral shedding.
The ability of DNA to induce protective correlates of immunity
to pathogenic influenza in a primate is an important step forward
for this technology. These responses, induced after only two
immunizations, can likely be enhanced with the addition of genetic
adjuvants such as IL-12 and IL-15 that ours and other labs have
reported on. These questions merit further study, as the ability to
induce such responses with a single vaccination would be very
useful in any vaccination campaign. The ability of these antigens
to protect from both morbidity and mortality in a ferret model of
HPAI, in both the presence and absence of neutralizing antibody,
may present an advantage for a vaccine that seeks to overcome the
antigenic drift that will likely occur before pandemic viruses cross
the species barrier to humans.
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